Drug intelligence / Profile preview

MBTC-MI-EVs

Development stage: Preclinical
Lead developer: Stemmedicare
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

MBTC-MI-EVs is an extracellular vesicle (EV)-based therapeutic candidate being developed by Stemmedicare for the treatment of heart failure and myocardial infarction. The drug utilizes Stemmedicare's proprietary immune-tolerized EV platform to facilitate cardiac repair and regeneration. By leveraging the natural signaling and cargo-delivery capabilities of EVs, the therapy aims to mitigate damage to cardiac tissue following an ischemic event and improve overall heart function. As of early 2024, the program is in the preclinical candidate stage of development.

Other names: MBTC-MI-EVs-Stemmedicare-extracellular vesicles (EVs)-Heart failure-Myocardial infarction

Beyond the preview

Go deeper on MBTC-MI-EVs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MBTC-MI-EVs.

Explore the full profile